GMA 301Alternative Names: GMA-301
Latest Information Update: 11 Jan 2017
At a glance
- Originator Gmax Biopharm
- Class Antihypertensives; Monoclonal antibodies
- Mechanism of Action Endothelin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Pulmonary arterial hypertension
Most Recent Events
- 10 Jan 2017 Early research in Pulmonary arterial hypertension in China (Parenteral) before January 2017 (Gmax Biopharm pipeline, January 2017)